1. Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice 
Antonio Alcaraz, Pierre Teillac 
European Urology Supplements 
Volume 5, Issue 3, Pages (April 2006)
DOI: /j.eursup
Copyright © 2006 Elsevier B.V. Terms and Conditions

2. Fig. 1
The majority of the delegates selected the combination of radiotherapy plus hormone therapy as preferred treatment option for this patient.
(a) Localized prostate cancer, specific patient case: 70 yr, T2b, Gleason 7 (4+3) on 6 of 10 cores, PSA level 16ng/ml, moderate symptoms, unfit for surgery, life expectancy about 10 yr.
AA=antiandrogen; LHRH=luteinizing hormone releasing hormone; HT=hormone therapy.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 Elsevier B.V. Terms and Conditions

3. Fig. 2
LHRH agonists seem to be the preferred treatment option for this patient.
(b) Advanced prostate cancer, specific patient case: 74 yr, T3b, N0, M0, Gleason 8 (4+4) on 8/10 cores, PSA level 20ng/ml, moderate symptoms, unfit for surgery, life expectancy about 5–10 yr.
AA=antiandrogen; LHRH=luteinizing hormone releasing hormone; HT=hormone therapy.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 Elsevier B.V. Terms and Conditions

4. Fig. 3
The majority of the delegates indicated that radiotherapy, closely followed by LHRH agonists, is the preferred treatment option for this patient suffering from biochemical recurrence after initial prostatectomy.
(c) Second-line therapy, specific patient case: 68 yr, PSA relapse 4 yr after initial radical prostatectomy (pT2a, PSA 7ng/ml, Gleason 6), PSA DT of 15 mo.
AA=antiandrogen; LHRH=luteinizing hormone releasing hormone.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 Elsevier B.V. Terms and Conditions

5. Fig. 4
Both LHRH agonists and combined androgen blockade seem to be the preferred treatment options for this specific patient.
(d) Positive nodes, specific patient case: 74 yr, 7 of 10 cores positive on biopsy, nodes >2cm on computed tomography scan, N+, Mx, Gleason 7 (4+3), PSA 32ng/ml, mild symptoms.
AA=antiandrogen; LHRH=luteinizing hormone releasing hormone; CAB=combined androgen blockade.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 Elsevier B.V. Terms and Conditions